文献速递胸部肿瘤

KRAS G12C突变对NSCLC患者预后的影响:欧洲胸部肿瘤平台Lungscape项目结果

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
PubMed 文献 · J Thorac Oncol · 2021-02-26

基于欧洲胸部肿瘤平台Lungscape 003多重突变研究,对2055例I–III期切除后NSCLC进行KRAS突变检测。腺癌队列KRAS突变率为38.0%,KRAS G12C占17.0%。校正临床病理特征后,KRAS G12C相较其他KRAS突变或无KRAS突变与更差预后显著相关。

要点

  • 腺癌队列KRAS突变率38.0%,其中KRAS G12C占17.0%
  • KRAS G12C vs 其他KRAS突变:腺癌总生存HR 1.39(95%CI 1.03–1.89,p=0.031)
  • KRAS G12C vs 无KRAS突变:全部患者无复发生存HR 1.27(95%CI 1.04–1.54,p=0.017)

核心结论

  • 在I–III期NSCLC大样本切除队列中,KRAS G12C突变在腺癌及未选择NSCLC中校正临床病理特征后与更差预后显著相关。

研究设计与样本

  • 研究为欧洲胸部肿瘤平台Lungscape 003多重突变研究的组成部分,采用微流控多重聚合酶链反应平台检测福尔马林固定石蜡包埋组织的KRAS突变。
  • 共检测2055例Lungscape病例,其中腺癌1014例(49%),I、II、III期分别占53%、24%、22%,中位随访57个月。

主要发现

  • 腺癌队列KRAS突变率为38.0%(95%CI 35.0%–41.0%),KRAS G12C占17.0%(95%CI 14.7%–19.4%)。
  • 组织学亚型队列中KRAS G12C阳性率为10.5%(95%CI 9.2%–11.9%)。
  • 腺癌总生存:KRAS G12C vs 其他KRAS突变HR 1.39(95%CI 1.03–1.89,p=0.031),vs 无KRAS突变HR 1.32(95%CI 1.03–1.69,p=0.028),两项在组织学亚型队列中亦显著。
  • 至复发时间:KRAS G12C vs 其他KRAS突变HR 1.41(95%CI 1.03–1.92,p=0.030)。
  • 全部患者无复发生存:KRAS G12C vs 无KRAS突变HR 1.27(95%CI 1.04–1.54,p=0.017)。

临床怎么用

  • 提示KRAS G12C可作为I–III期切除后NSCLC,尤其腺癌的预后分层参考指标。
  • 为KRAS G12C共价抑制剂(AMG-510、MRTX849)相关临床研究的人群选择与预后评估提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: KRAS mutations, the most frequent gain-of-function alterations in NSCLC, are currently emerging as potential predictive therapeutic targets. The role of KRAS-G12C (Kr_G12C) is of special interest after the recent discovery and preclinical analyses of two different Kr_G12C covalent inhibitors (AMG-510, MRTX849). METHODS: KRAS mutations were evaluated in formalin-fixed, paraffin-embedded tissue sections by a microfluidic-based multiplex polymerase chain reaction platform as a component of the previously published European Thoracic Oncology Platform Lungscape 003 Multiplex Mutation study, of clinically annotated, resected, stage I to III NSCLC. In this study, -Kr_G12C mutation prevalence and its association with clinicopathologic characteristics, molecular profiles, and postoperative patient outcome (overall survival, relapse-free survival, time-to-relapse) were explored. RESULTS: KRAS gene was tested in 2055 Lungscape cases (adenocarcinomas: 1014 [49%]) with I or II or III stage respective distribution of 53% or 24% or 22% and median follow-up of 57 months. KRAS mutation prevalence in the adenocarcinoma cohort was 38.0% (95% confidence interval (CI): 35.0% to 41.0%), with Kr_G12C mutation representing 17.0% (95% CI: 14.7% to 19.4%). In the "histologic-subtype" cohort, Kr_G12C prevalence was 10.5% (95% CI: 9.2% to 11.9%). When adjusting for clinicopathologic characteristics, a significant negative prognostic effect of Kr_G12C presence versus other KRAS mutations or nonexistence of KRAS mutation was identified in the adenocarcinoma cohort alone and in the "histologic-subtype" cohort. For overall survival in adenocarcinomas, hazard ratio (HR)G12C versus other KRAS is equal to 1.39 (95% CI: 1.03 to 1.89, p = 0.031) and HRG12C versus no KRAS is equal to 1.32 (95% CI: 1.03 to 1.69, p = 0.028) (both also significant in the "histologic-subtype" cohort). For time-to-relapse, HRG12C versus other KRAS is equal to 1.41 (95% CI: 1.03 to 1.92, p = 0.030). In addition, among all patients, for relapse-free survival, HRG12C versus no KRAS is equal to 1.27 (95% CI: 1.04 to 1.54, p = 0.017). CONCLUSIONS: In this large, clinically annotated stage I to III NSCLC cohort, the specific Kr_G12C mutation is significantly associated with poorer prognosis (adjusting for clinicopathologic characteristics) among adenocarcinomas and in unselected NSCLCs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Finn SP, Addeo A, Dafni U, et al. Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2021. PMID: 33647504. doi:10.1016/j.jtho.2021.02.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。